

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
16/LO/0423	198451	A Phase I trial of CCT245737 (a CHK1 inhibitor) administered orally inpatients with advanced cancer	Number Agreed	10	10	Date Agreed	01/07/2018	3	01/07/2018	3	Recruitment Finished
17/EE/0079	220827	A Randomized, double-blind, placebo-controlled, phase 3 study to evaluate the safety and efficacy of CCX168 in patients with anti-neutrophil cytoplasmic antibody (ANCA)- Associated Vasculitis Treated Concomitantly with Rituximab or Cyclophosphamide/	Number Agreed	2	2	Date Agreed	04/07/2018	1	04/07/2018	1	Recruitment Finished
17/WS/0071	224151	An International, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effect of Dapagliflozin on the Incidence of the composite of =40% sustained reduction in eGFR, entering ESRD, CV or Renal Death in patients with Albu	Number Agreed	8	8	Date Agreed	06/07/2018	8	06/07/2018	8	Recruitment Finished
18/ES/0013	240837	PRospective Observation of aortic reGuRgitation aTer TAVI and progreSS over time: PROGRESS PVL Registry	Number Agreed	6	6	Date Agreed	30/07/2018	3	30/07/2018	3	Recruitment Finished
17/LO/1451	229939	A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Multicenter Study to Evaluate the Efficacy and Safety of Sotagliflozin in Patients with Type 2 Diabetes Who Have Inadequate Glycemic Control on Basal Insulin Alone or in Addition	Number Agreed	5	5	Date Agreed	03/08/2018	0	03/08/2018	0	Recruitment Finished
17/EE/0264	228153	POSEIDON - A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for First-Line Treatment in Patients With Me	Number Agreed	6	6	Date Agreed	07/08/2018	7	07/08/2018	7	Recruitment Finished
17/NE/0377	233847	A phase 3b, multicenter, prospective, randomized, double blind, placebo-controlled study to reduce the incidence of pre-dialysis hyperkalemia with Sodium Zirconium Cyclosilicate (DIALIZE)	Number Agreed	6	6	Date Agreed	14/08/2018	12	14/08/2018	12	Recruitment Finished
16/LO/0092	194133	A PHASE Ib/II STUDY EVALUATING THE SAFETY AND EFFICACY OF OBINUTUZUMAB IN COMBINATION WITH POLATUZUMAB VEDOTIN AND LENALIDOMIDE IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR OR DIFFUSE LARGE B-CELL LYMPHOMA	Number Agreed	4	4	Date Agreed	24/08/2018	4	24/08/2018	4	Recruitment Finished

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
15/EM/0500	188865	A 52-week, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of QAW039 when added to existing asthma therapy in patients with uncontrolled severe eosinophilic asthma	Number Agreed	6	6	Date Agreed	20/09/2018	3	20/09/2018	3	Recruitment Finished
17/EE/0255	227279	A DOUBLE-BLIND, RANDOMISED, PLACEBO CONTROLLED STUDY OF THE EFFICACY AND SAFETY OF THREE DOSES OF ORVEPITANT IN PATIENTS WITH CHRONIC REFRACTORY COUGH	Number Agreed	6	6	Date Agreed	28/09/2018	9	28/09/2018	9	Recruitment Finished
15/NE/0167	171524	A Phase 3, Randomized, Placebo-Controlled, Double-Blind Study of Oral Ixazomib Maintenance Therapy After Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma Not Treated With Stem Cell Transplantation	Number Agreed	4	4	Date Agreed	03/10/2018	12	03/10/2018	12	Recruitment Finished
17/LO/0085	216434	Phase 3, Randomized, Open-Label, Active-Controlled Study Evaluating the Efficacy and Safety of Oral Vadadustat for the Maintenance Treatment of Anemia in Subjects with Dialysis-Dependent Chronic Kidney Disease (DD-CKD) (INNO2VATE ? CONVERSION)	Number Agreed	1	1	Date Agreed	22/10/2018	3	22/10/2018	3	Recruitment Finished
18/NW/0173	242176	Effect and safety of semaglutide 2.4 mg once-weekly in subjects with overweight or obesity and type 2 diabetes	Number Agreed	8	8	Date Agreed	05/11/2018	8	05/11/2018	8	Recruitment Finished
16/EM/0422	209463	A randomized, double-blind, placebo-controlled study to investigate the efficacy and safety of mepolizumab in the treatment of adolescent and adult subjects with severe hypereosinophilic syndrome	Number Agreed	2	2	Date Agreed	06/11/2018	6	06/11/2018	6	Recruitment Finished
17/EM/0367	231327	A multi-centre, open-label extension, safety study to describe the long-term clinical experience of mepolizumab in participants with hypereosinophilic syndrome (HES) from Study 200622	Number Agreed	4	4	Date Agreed	06/11/2018	6	06/11/2018	6	Recruitment Finished
17/LO/1656	229212	A phase III, open-label, multicenter, two-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab versus pembrolizumab in patients with previously untreated advanced brafv600 wild-type melanoma	Number Agreed	3	3	Date Agreed	08/11/2018	3	08/11/2018	3	Recruitment Finished

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
16/EM/0193	190690	A phase III, double-blind, randomized placebo-controlled study to evaluate the effects of dalcetrapib on cardiovascular (CV) risk in a genetically defined population with a recent Acute Coronary Syndrome (ACS): The Dal-GenE trial	Number Agreed	6	6	Date Agreed	12/11/2018	8	12/11/2018	8	Recruitment Finished
16/WM/0317	206807	Randomized Efficacy and Safety Trial with Oral S44819 after recent ischaemic cerebral event.International, multi-centre, randomized, double-blind placebo-controlled phase II study.	Number Agreed	8	8	Date Agreed	15/11/2018	12	15/11/2018	12	Recruitment Finished
16/LO/1822	212944	A randomized parallel-group, placebo-controlled, double-blind, event-driven, multi-center pivotal phase III clinical outcome trial of efficacy and safety of the oral sGC stimulator Vericiguat in subjects with heart failure and reduced ejection fracti	Number Agreed	3	3	Date Agreed	29/11/2018	3	29/11/2018	3	Recruitment Finished
16/LO/0521	191745	A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination with Tremelimumab or AZD9150 in Subjects with Relapsed or Refractory Diffuse Large B-cell Lymphoma	Number Agreed	1	1	Date Agreed	05/12/2018	2	05/12/2018	2	Recruitment Finished
13/LO/0418	112763	A multi-centre, randomised, placebo controlled double blind, two armed, parallel group study to evaluate efficacy and safety of IV Sildenafil in the treatment of neonates persistent pulmonary hypertension of the newborn (PPHN) or hypoxic respiratory	Number Agreed	1	1	Date Agreed	31/12/2018	5	31/12/2018	5	Recruitment Finished
15/YH/0478	186697	A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects with Nonalcoholic Steatohepatitis	Number Agreed	8	8	Date Agreed	31/01/2019	0	31/01/2019	0	Recruitment Finished
17/LO/1068	224973	A PHASE III RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED MULTICENTER TRIAL TESTING IPATASERTIB PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE RELATIVE TO PLACEBO PLUS ABIRATERONE PLUS PREDNISONE/PREDNISOLONE IN ADULT MALE PATIENTS WITH ASYMPTOMATIC OR M	Number Agreed	4	4	Date Agreed	31/01/2019	9	31/01/2019	9	Recruitment Finished

REC No	IRAS No	Name of Trial	Target Number Of Patients Agreed?	Minimum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Maximum Number Of Patients Agreed (Enter Same In Both If Only One Number)	Target Date To Recruit Patients Agreed?	Date Agreed to recruit target number of patients	Total Number Of Patients Recruited At The Agreed Target Date	Date That The Trial Closed To Recruitment	Total Number Of Study Participants Recruited	Reason For Closure Of Trial
17/SC/0083	218035	A Prospective, Randomized, Open Label, Multi-center Study of the Safety and Pharmacokinetics of Apixaban versus Vitamin K Antagonist or Low Molecular Weight Heparin in Pediatric Subjects with Congenital or Acquired Heart Disease Requiring Chronic Ant	Number Agreed	3	3	Date Agreed	22/03/2019	6	22/03/2019	6	Recruitment Finished
17/EM/0063	213979	A Phase 3 Multi-Center, Randomized, Double-Blind, Placebo-Controlled Trial of the FLT3 Inhibitor Gilteritinab (ASP2215) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects with FLT3/ITD AML in First Complete Rem	Number Agreed	2	2	Date Agreed	29/03/2019	0	29/03/2019	0	Recruitment Finished
16/LO/0422	198606	A Phase I trial of oral CCT245737 (a CHK1 inhibitor) given in combination with gemcitabine plus cisplatin or gemcitabine alone in patients with advanced cancer	Number Agreed	5	5	Date Agreed	03/05/2019	5	03/05/2019	5	Recruitment Finished
17/SW/0221	232448	A randomized, partially-blinded, active-controlled, multicenter study of secukinumab to demonstrate reduction of radiographic progression versus GP2017 (adalimumab biosimilar) at 104 weeks and to assess the long term safety, tolerability and efficacy	Number Agreed	4	4	Date Agreed	16/05/2019	1	16/05/2019	1	Recruitment Finished
17/WS/0072	221444	EDOXABAN VERSUS STANDARD OF CARE AND THEIR EFFECTS ON CLINICAL OUTCOMES IN PATIENTS HAVING UNDERGONE TRANSCATHETER AORTIC VALVE IMPLANTATION ? IN ATRIAL FIBRILLATION	Not Available / Not Agreed			Date Agreed	31/05/2019	0	31/05/2019	0	Withdrawn By Sponsor
18/LO/1301	249407	VIVO Accuracy Study	Number Agreed	6	6	Date Agreed	14/06/2019	6	14/06/2019	6	Recruitment Finished
18/EE/0092	235968	A randomised, double-blind (sponsor unblind), placebo-controlled, multi-centred phase IIa study to evaluate the safety and efficacy of 13 weeks of once daily oral dosing of the selective androgen receptor modulator (SARM) GSK2881078 in older men and	Number Agreed	8	8	Date Agreed	24/06/2019	7	24/06/2019	7	Recruitment Finished